

**P&T Motion History**  
**Hepatitis C – Direct-Acting Antivirals**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
daclastavir <b>glecaprevir/pibrentasvir</b> grazoprevir/elbasvir ledipasvir/sofosbuvir paritaprevir/ritonavir/ombitasvir paritaprevir/rit/ombitasvir/dasabuvir simeprevir sofosbuvir velpatasvir/sofosbuvir <b>voxilaprevir/velpatasvir/sofosbuvir</b>	<p><b>Hepatitis C – Genotype 1-6</b>            After considering the evidence of safety, efficacy and special populations for the treatment of Hepatitis C, I move that</p> <p>daclastavir  <b>glecaprevir/pibrentasvir</b>            grazoprevir/elbasvir            ledipasvir/sofosbuvir            paritaprevir/ritonavir/ombitasvir            paritaprevir/rit/ombitasvir/dasabuvir            simeprevir            sofosbuvir            velpatasvir/sofosbuvir  <b>voxilaprevir/velpatasvir/sofosbuvir</b></p> <p>are safe and efficacious for their FDA approved indications. These drugs cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p><b>Motion: Chew</b>  <b>2<sup>nd</sup>: Figueroa</b></p>	October 18, 2017	NA	No	Passed unanimous